UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers

PloS one, 2017-12, Vol.12 (12), p.e0189953-e0189953

2017

Volltextzugriff (PDF)

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment

Clinical cancer research, 2009-10, Vol.15 (19), p.6258-6266

2009

Volltextzugriff (PDF)

c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells

Molecular cancer research, 2011-08, Vol.9 (8), p.1054-1066

2011

Volltextzugriff (PDF)

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Cancer Research and Treatment, 2018, 50(2), , pp.398-404

2018

Volltextzugriff (PDF)

Bone Sialoprotein Is Predictive of Bone Metastases in Resectable Non–Small-Cell Lung Cancer: A Retrospective Case-Control Study

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4818-4824

2006

Volltextzugriff (PDF)

The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts

The Journal of biological chemistry, 1997-12, Vol.272 (49), p.30822-30827

1997

Volltextzugriff (PDF)

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models

Clinical cancer drugs, 2018-01, Vol.5 (1), p.42-49

2018

Volltextzugriff (PDF)

Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies

Pharmacology & therapeutics (Oxford), 2017-02, Vol.170, p.8-13

2017

Volltextzugriff (PDF)

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Clinical cancer research, 2016-10, Vol.22 (20), p.5049-5057

2016

Volltextzugriff (PDF)

Epigenetic Changes: Potential Therapeutic Targets

Annals of the New York Academy of Sciences, 2003-03, Vol.983 (1), p.278-285

KALEBIC, THEA

2003

Volltextzugriff (PDF)

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Investigational new drugs, 2017-10, Vol.35 (5), p.634-641

2017

Volltextzugriff (PDF)

The Role of the Tyrosine Kinase Domain of the Insulin-like Growth Factor-I Receptor in Intracellular Signaling, Cellular Proliferation, and Tumorigenesis

The Journal of biological chemistry, 1995-12, Vol.270 (49), p.29176-29181

1995

Volltextzugriff (PDF)

Expression of a kinase‐deficient IGF‐I‐R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF‐I‐R

International journal of cancer, 1998-04, Vol.76 (2), p.223-227

1998

Volltextzugriff (PDF)

Phase I Study of the Investigational Anti-Guanylyl Cyclase AntibodyDrug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Clinical cancer research, 2016-10, Vol.22 (20), p.5049-5057

2016

Volltextzugriff (PDF)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Investigational new drugs, 2015-06, Vol.33 (3), p.652-663

2015

Volltextzugriff (PDF)

Abstract B050: Evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B050-B050

2018

Volltextzugriff (PDF)

Bcr-Abl Kinetics Suggest Self-Renewing Leukemic Cells Are Reduced During Imatinib Treatment

Blood, 2009-11, Vol.114 (22), p.506-506

2009

Volltextzugriff (PDF)

Abstract CT107: Phase II trial of TAK-264 in previously treated patients (pts) with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expression guanylyl cyclase C (GCC)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT107-CT107

2016

Volltextzugriff (PDF)

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

Investigational new drugs, 2017-04, Vol.35 (2), p.235-241

2017

Volltextzugriff (PDF)

Epigenetic transitions: towards therapeutic targets

Expert opinion on therapeutic targets, 2003-12, Vol.7 (6), p.693-699

Kalebic, Thea

2003

Volltextzugriff (PDF)

Abstract 4948: PET/CT clinical protocol design for the novel, first in class 68Ga labeled guanylyl cyclase C targeted peptide MLN6907 ([68Ga]MLN6907)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4948-4948

2014

Volltextzugriff (PDF)

MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3546-3546

2014

Volltextzugriff (PDF)

Abstract CT117: A phase II trial of TAK-264, a novel antibody-drug conjugate (ADC), in patients with pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT117-CT117

2016

Volltextzugriff (PDF)

Enhancing enrollment using cohort surveillance for phase II biomarkers driven studies in patients with gastric/GEJ and pancreatic cancer

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15017-e15017

2015

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(68)

Sprache

Englisch
(68)

Erscheinungsjahr

n.n

Thema

Humans
(25)
Science & Technology
(25)
Life Sciences & Biomedicine
(22)
Oncology
(16)
Biological And Medical Sciences
(12)
Animals
(9)
Male
(9)
Medical Sciences
(9)
Antineoplastic Agents - Therapeutic Use
(8)
Female
(8)
Middle Aged
(8)
Aged
(7)
Mice
(7)
Adult
(6)
Mice, Nude
(6)
Pharmacology. Drug Treatments
(6)
Aids/hiv
(5)
Tumors
(5)
Antineoplastic Agents
(4)
Cell Line
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment

c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Bone Sialoprotein Is Predictive of Bone Metastases in Resectable Non–Small-Cell Lung Cancer: A Retrospective Case-Control Study

The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models

Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Epigenetic Changes: Potential Therapeutic Targets

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

The Role of the Tyrosine Kinase Domain of the Insulin-like Growth Factor-I Receptor in Intracellular Signaling, Cellular Proliferation, and Tumorigenesis

Expression of a kinase‐deficient IGF‐I‐R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF‐I‐R

Phase I Study of the Investigational Anti-Guanylyl Cyclase AntibodyDrug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Abstract B050: Evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Bcr-Abl Kinetics Suggest Self-Renewing Leukemic Cells Are Reduced During Imatinib Treatment

Abstract CT107: Phase II trial of TAK-264 in previously treated patients (pts) with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expression guanylyl cyclase C (GCC)

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

Epigenetic transitions: towards therapeutic targets

Abstract 4948: PET/CT clinical protocol design for the novel, first in class 68Ga labeled guanylyl cyclase C targeted peptide MLN6907 ([68Ga]MLN6907)

MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study

Abstract CT117: A phase II trial of TAK-264, a novel antibody-drug conjugate (ADC), in patients with pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)

Enhancing enrollment using cohort surveillance for phase II biomarkers driven studies in patients with gastric/GEJ and pancreatic cancer

Suchergebnisse filtern